Golimumab vs placebo for early type 1 diabetes
Treatments studied
Part of Hormones & metabolism, Immune system & allergy clinical trials.
This study tests whether a medicine called golimumab can slow down or stop type 1 diabetes from getting worse in people who are in the earliest stage of the disease. Participants are randomly assigned to receive either golimumab or a placebo (a dummy shot) to see if the medicine helps protect the body's insulin-making cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 2 and 44 years old and weigh at least 15 kg (about 33 pounds).
- You must have certain diabetes-related autoantibodies in your blood (confirmed twice) that show you are at risk for type 1 diabetes.
- Your blood sugar must be normal based on a special glucose tolerance test done within the last 7 weeks.
- You must not have used insulin except during an illness or hospital stay.
- You must be up to date on recommended vaccines and avoid live vaccines during the study.
- You must be in good general health with no active infections, tuberculosis, or other autoimmune diseases (except well-controlled thyroid or celiac disease).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a medicine called anti-thymocyte globulin (h-ATG) to see if it can help people with type 1 diabetes keep making some of their own insulin. It may slow the loss of insulin-making cells and help manage blood sugar.
This trial tests an investigational drug that may help preserve the body's ability to make insulin in people with type 1 diabetes. It aims to slow the progression of the disease and reduce the need for insulin injections.
This study follows people of all ages who have a positive islet autoantibody test but no diabetes symptoms yet. It aims to track them over time to learn more about how type 1 diabetes develops, which may lead to better prevention and care.
This study tests a low dose of a drug that calms the immune system, followed by either another immune drug or a blood pressure medicine, to see if they can help preserve the body's ability to make insulin in people recently diagnosed with type 1 diabetes. It may help keep your own insulin production going longer.
This study compares two medicines (teplizumab and anti-thymocyte globulin) to see if they can delay the onset of type 1 diabetes in people who are at high risk but don't have symptoms yet. If you have certain diabetes-related antibodies in your blood, this trial might help keep full-blown diabetes away for longer.
This trial tests a new way to give a medicine called anti-thymocyte globulin (ATG) with or without verapamil, a blood pressure drug. It aims to slow down the loss of insulin-making cells in people newly diagnosed with type 1 diabetes.
Hear when a new Type 1 Diabetes (T1D) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.